PMID- 28940139
OWN - NLM
STAT- In-Process
LR  - 20190129
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
VI  - 38
IP  - 1
DP  - 2019 Jan
TI  - Normal serum matrix metalloproteinase-3 levels can be used to predict clinical
      remission and normal physical function in patients with rheumatoid arthritis.
PG  - 181-187
LID - 10.1007/s10067-017-3829-9 [doi]
AB  - This study aimed to evaluate whether normal serum matrix metalloproteinase-3
      (MMP-3) levels can be used to predict clinical remission and normal physical
      function at a single time point when treating patients with rheumatoid arthritis 
      (RA) in daily practice settings. Subjects were all 1321 RA patients who were
      treated at our hospital. The accuracy of serum MMP-3 levels was larger than those
      of C-reactive protein (CRP) levels for predicting clinical remission [Simplified 
      Disease Activity Index (SDAI) </= 3.3], normal function [Disability Index of the 
      Health Assessment Questionnaire (HAQ-DI) </= 0.5], and both in clinical remission
      and with normal function (clinical remission + normal function) using receiver
      operating characteristic curve analysis. Serum MMP-3 levels were significantly
      correlated with CRP levels [r 0.229 (men), r 0.476 (women)] using Pearson's
      correlation coefficients. Among patients with normal CRP levels (n = 807), the
      percentage of patients in clinical remission, with normal function, and with
      clinical remission + normal function having normal serum MMP-3 levels was
      significantly higher than those with abnormal serum MMP-3 levels. In addition,
      among patients with the 28-point count Disease Activity Score-CRP (DAS28-CRP)
      remission (DAS28-CRP < 2.3), the percentage of patients in clinical remission,
      with normal function, and with clinical remission + normal function having normal
      serum MMP-3 levels was significantly higher than those with abnormal serum MMP-3 
      levels. Our findings suggest that normal serum MMP-3 levels, in combination with 
      CRP levels or disease activity, are useful for predicting clinical remission and 
      normal physical function in patients with RA.
FAU - Hattori, Yosuke
AU  - Hattori Y
AUID- ORCID: http://orcid.org/0000-0002-2354-3070
AD  - National Hospital Organization Nagoya Medical Center, Orthopaedic Surgery and
      Rheumatology, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan.
      hattori2002@gmail.com.
FAU - Kida, Daihei
AU  - Kida D
AD  - National Hospital Organization Nagoya Medical Center, Orthopaedic Surgery and
      Rheumatology, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan.
FAU - Kaneko, Atsushi
AU  - Kaneko A
AD  - National Hospital Organization Nagoya Medical Center, Orthopaedic Surgery and
      Rheumatology, 4-1-1 Sannomaru, Naka-ku, Nagoya, Aichi, 460-0001, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170922
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
OTO - NOTNLM
OT  - Clinical remission
OT  - MMP-3
OT  - Matrix metalloproteinase-3
OT  - Physical function
OT  - Rheumatoid arthritis
EDAT- 2017/09/25 06:00
MHDA- 2017/09/25 06:00
CRDT- 2017/09/24 06:00
PHST- 2017/08/21 00:00 [received]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2017/09/25 06:00 [pubmed]
PHST- 2017/09/25 06:00 [medline]
PHST- 2017/09/24 06:00 [entrez]
AID - 10.1007/s10067-017-3829-9 [doi]
AID - 10.1007/s10067-017-3829-9 [pii]
PST - ppublish
SO  - Clin Rheumatol. 2019 Jan;38(1):181-187. doi: 10.1007/s10067-017-3829-9. Epub 2017
      Sep 22.